All About Multiple Sclerosis

More MS news articles for March 2003

Effects of combination therapy of beta-interferon 1a and prednisone on serum immunologic markers in patients with multiple sclerosis

http://www.ingenta.com/isis/searching/ExpandTOC/ingenta?issue=infobike://arn/ms/2003/00000009/00000001&index=5

Multiple Sclerosis, 1 February 2003, vol. 9, no. 1, pp. 28-31(4)
Salama H.H.[1]; Kolar O.J.[2]; Zang Y.C.[3]; Zhang J.[3]
[1] Multiple Sclerosis Research Unit, Department of Neurology, Baylor-Methodist Multiple Sclerosis Center, Houston, TX 77030, USA and Department of Neurology, Faculty of Medicine, Mansura University, Mansura, Egypt [2] Indiana Center for Multiple Sclerosis and Neuroimmunopathologic Disorders, Indianapolis, IN 48260, USA [3] Multiple Sclerosis Research Unit, Department of Neurology, Baylor-Methodist Multiple Sclerosis Center, Houston, TX 77030, USA and Department of Immunology, Baylor College of Medicine, Houston, TX 77030, USA

Beta-interferon (beta-IFN) has a proven treatment effect on relapsing–remitting multiple sclerosis (MS), presumably through its regulatory properties on T-cell activation and cytokine production.

This paper examines whether combination therapy of beta-IFN with prednisone would enhance immunoregulatory effects of beta-IFN by measuring serum levels of selected proinflammatory cytokines and soluble T-cell activation markers associated with MS.

The selected markers were analyzed in MS patients treated with beta-IFN alone (n = 22) and beta-IFN combined with a low daily dose of prednisone (n =33), as compared with those in 27 healthy controls at baseline and at a three-month interval for one year.

The study confirmed that beta-IFN treatment inhibited serum levels of tumor necrosis factor-alpha (TNFa) and intracellular adhesion molecule-1 (IC AM-1) in patients with MS.

However, combination therapy did not significantly enhance the inhibitory effect of beta-IFN treatment on the production of TNF, interleukin (IL)-12, IL-2R, and ICAM-1, while the addition of prednisone antagonized the effect of beta-IFN on up-regulation of IL-10 and soluble CD95.

No difference in the occurrence of binding antibodies to beta-IFN was found between the two treatment groups.

The findings are important for the understanding of the role of combination therapy in the treatment of MS.